WEGOVY® FLEXTOUCH 0.5mg

Description

Wegovy® FlexTouch 0.5mg is a prescription medicine formulated for weight management in adults and adolescents aged 12 and above. It is designed as a weekly subcutaneous injection containing semaglutide, a GLP-1 receptor agonist that regulates appetite and food intake.

Target use: Adults with a BMI ≥30 kg/m² (obesity), or ≥27 kg/m² with weight-related comorbidities like type 2 diabetes, hypertension, or sleep apnoea.

Active ingredient: Each 0.5mg dose contains semaglutide, a GLP-1 analogue produced via recombinant DNA technology in Saccharomyces cerevisiae.

Therapeutic effect: Promotes weight loss by reducing appetite, increasing satiety, and lowering caloric intake.

Key Features

Dose Precision: Delivers four individual doses of 0.5mg semaglutide per pen.

Weekly Administration: Supports long-term weight management with once-weekly dosing.

Clinically Proven: Demonstrated average body weight reduction of 9.6% over 68 weeks in adults with type 2 diabetes.

Common Side Effects:

Nausea (43.9%)
Diarrhoea (29.7%)
Constipation (24.2%)
Vomiting (24.5%)
Headache, dizziness, and increased heart rate.
Serious Risks:
Acute pancreatitis (0.2%)
Cholelithiasis (1.6%) and cholecystitis (0.6%)
Hair loss (2.5%) and injection site reactions